首页 > 最新文献

Dermatologic Therapy最新文献

英文 中文
The Impact of Growth Factors in Platelet-Rich Plasma Combination Therapy for Androgenic Alopecia 生长因子在富血小板血浆联合疗法中对雄激素性脱发的影响
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-07-18 DOI: 10.1155/2024/8452387
Jie Ren, Jingxuan Sun, Zhenghui Li, Yi Zhao, Hsiaohan Tuan

The efficacy of platelet-rich plasma (PRP) therapy for androgenic alopecia (AGA) varies among diverse populations. While prior research has emphasized the pivotal role of growth factors as active components in PRP, the specific relationship between growth factors and treatment outcomes of AGA remains unclear. This study aims to explore how the efficacy of PRP therapy for AGA is influenced by the types and concentrations of growth factors. The analysis of PRP samples from 46 AGA patients involved assessing seven growth factors using an enzyme-linked immunosorbent assay. Patients received a course of three PRP treatments along with traditional medicines. The assessment of treatment outcomes involved conducting trichoscopy tests before and after the treatment, measuring both hair density (HD) and hair caliber (HC). The findings revealed that HD increased in 36 patients, positively correlating with glial cell-derived neurotrophic factor (GDNF) concentration (p = 0.005). In addition, HC increased in 35 patients, demonstrating a positive correlation with platelet-derived growth factor-BB (PDGF-BB) concentration (p < 0.05). Notably, a gender-based analysis identified a statistically significant difference in HC increase post-PRP therapy (p = 0.005). In addition, no correlations were observed between demographic factors and changes in HD/HC (p > 0.05). The study confirms the beneficial influence of certain growth factors in PRP on AGA treatment outcomes. Future research should further clarify their mechanisms in promoting hair growth, paving the way for the development of novel therapeutic agents.

富血小板血浆(PRP)疗法对雄激素性脱发(AGA)的疗效因人而异。虽然先前的研究强调了生长因子作为 PRP 中活性成分的关键作用,但生长因子与 AGA 治疗效果之间的具体关系仍不清楚。本研究旨在探讨生长因子的类型和浓度如何影响 PRP 治疗 AGA 的疗效。对 46 例 AGA 患者的 PRP 样品进行的分析包括使用酶联免疫吸附测定法评估七种生长因子。患者在接受传统药物治疗的同时,还接受了三个疗程的 PRP 治疗。对治疗效果的评估包括在治疗前后进行毛发镜检查,测量毛发密度(HD)和毛发直径(HC)。结果显示,36 名患者的毛发密度增加,与胶质细胞源性神经营养因子(GDNF)浓度呈正相关(p = 0.005)。此外,35 名患者的 HC 增加,与血小板衍生生长因子-BB(PDGF-BB)浓度呈正相关(p < 0.05)。值得注意的是,基于性别的分析发现,PRP 治疗后 HC 的增加具有显著的统计学差异(p = 0.005)。此外,人口统计学因素与 HD/HC 的变化之间没有相关性(p > 0.05)。该研究证实了 PRP 中的某些生长因子对 AGA 治疗结果的有利影响。未来的研究应进一步阐明其促进毛发生长的机制,为开发新型治疗药物铺平道路。
{"title":"The Impact of Growth Factors in Platelet-Rich Plasma Combination Therapy for Androgenic Alopecia","authors":"Jie Ren,&nbsp;Jingxuan Sun,&nbsp;Zhenghui Li,&nbsp;Yi Zhao,&nbsp;Hsiaohan Tuan","doi":"10.1155/2024/8452387","DOIUrl":"https://doi.org/10.1155/2024/8452387","url":null,"abstract":"<div>\u0000 <p>The efficacy of platelet-rich plasma (PRP) therapy for androgenic alopecia (AGA) varies among diverse populations. While prior research has emphasized the pivotal role of growth factors as active components in PRP, the specific relationship between growth factors and treatment outcomes of AGA remains unclear. This study aims to explore how the efficacy of PRP therapy for AGA is influenced by the types and concentrations of growth factors. The analysis of PRP samples from 46 AGA patients involved assessing seven growth factors using an enzyme-linked immunosorbent assay. Patients received a course of three PRP treatments along with traditional medicines. The assessment of treatment outcomes involved conducting trichoscopy tests before and after the treatment, measuring both hair density (HD) and hair caliber (HC). The findings revealed that HD increased in 36 patients, positively correlating with glial cell-derived neurotrophic factor (GDNF) concentration (<i>p</i> = 0.005). In addition, HC increased in 35 patients, demonstrating a positive correlation with platelet-derived growth factor-BB (PDGF-BB) concentration (<i>p</i> &lt; 0.05). Notably, a gender-based analysis identified a statistically significant difference in HC increase post-PRP therapy (<i>p</i> = 0.005). In addition, no correlations were observed between demographic factors and changes in HD/HC (<i>p</i> &gt; 0.05). The study confirms the beneficial influence of certain growth factors in PRP on AGA treatment outcomes. Future research should further clarify their mechanisms in promoting hair growth, paving the way for the development of novel therapeutic agents.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8452387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141639554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain Risankizumab 对 Ustekinumab 反应不佳或失败患者的疗效:西班牙一项多中心回顾性研究
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-07-10 DOI: 10.1155/2024/5528484
Jorge Magdaleno-Tapial, José María Ortiz-Salvador, José Luis Sánchez-Carazo, Pablo Hernández-Bel, Amparo Pérez-Ferriols, Sergio Santos-Alarcón, Antonio Sahuquillo-Torralba, Conrad Pujol-Marco, Raquel Rivera-Díaz, Isabel Belinchón-Romero, Diana Ruiz-Geneao, Alberto Romero-Maté, Ricardo Ruiz-Villaverde, Marta Ferrán-Farrés, Fernando Gallardo-Hernández, Manuel Almenara-Blasco, Jorge Alonso-Suárez, Álvaro González-Cantero, Elena Martínez-Lorenzo, José Manuel Fernández-Armenteros, Elena de Alcázar-Viladomiu, Javier García-Latasa, Vicenç Rocamora-Durant, Mariano Ara-Martín, Almudena Mateu-Puchades, Mar Llamas-Velasco, Eva Vilarrasa-Rull, Manel Velasco-Pastor, Pablo de la Cueva-Dobao, José Manuel Carrascosa-Carrillo, Antonio Martorell-Calatayud

Background. Current psoriasis treatment goals emphasize achieving complete or near-complete skin clearance while preserving the quality of life, necessitating treatment modification for a suboptimal or inadequate response. Despite risankizumab’s demonstrated efficacy, evidence remains limited for patients switching from ustekinumab, particularly those with suboptimal or inadequate response. Objective. This study assesses risankizumab’s real-world effectiveness in patients with suboptimal response (PASI 2-3), inadequate response (PASI 3–5), or failure (PASI >5) to ustekinumab, based on a multicenter retrospective cohort in Spain. Method. A multicenter retrospective study across 24 Spanish hospitals included 102 patients previously treated with ustekinumab and switched to risankizumab. Results. Out of 102 patients, 78 experienced ustekinumab treatment failure (PASI >5), while 24 had an inadequate response (PASI 3–5), including 6 with a suboptimal response (PASI 2-3). Remarkably, after one year of treatment with risankizumab, all patients demonstrated improvement, achieving near-complete or complete skin clearance (PASI 0-1). Conclusion. Risankizumab displayed effectiveness in patients with suboptimal/inadequate response or treatment failure to ustekinumab, aligning with the current treatment goals of complete or near-complete skin clearance. These real-world results corroborate clinical trial data, emphasizing risankizumab’s potential as a powerful therapeutic alternative for this patient population. Further prospective studies are essential to validate these findings.

背景。目前的银屑病治疗目标强调在保持生活质量的同时,实现完全或接近完全的皮肤清除,这就要求对反应不理想或不充分的患者进行治疗调整。尽管利桑珠单抗的疗效已得到证实,但对于从乌司替尼转为利桑珠单抗治疗的患者,尤其是那些疗效不理想或疗效不佳的患者,相关证据仍然有限。研究目的本研究以西班牙的一个多中心回顾性队列为基础,评估了利坦珠单抗对乌斯特库单抗反应不理想(PASI 2-3)、反应不充分(PASI 3-5)或失败(PASI >5)患者的实际疗效。研究方法在西班牙24家医院开展的一项多中心回顾性研究纳入了102名曾接受过乌司替库单抗治疗后转用利坦单抗的患者。结果在102名患者中,78人经历了乌司替尼治疗失败(PASI 5),24人反应不充分(PASI 3-5),其中6人反应不理想(PASI 2-3)。值得注意的是,使用利桑单抗治疗一年后,所有患者的病情都得到了改善,皮肤接近完全或完全清除(PASI 0-1)。结论利坦珠单抗对乌司替库单抗反应不理想/不充分或治疗失败的患者有效,符合目前完全或接近完全皮肤清除的治疗目标。这些真实世界的结果证实了临床试验数据,强调了利坦珠单抗作为这一患者群体的有力替代疗法的潜力。进一步的前瞻性研究对验证这些发现至关重要。
{"title":"Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain","authors":"Jorge Magdaleno-Tapial,&nbsp;José María Ortiz-Salvador,&nbsp;José Luis Sánchez-Carazo,&nbsp;Pablo Hernández-Bel,&nbsp;Amparo Pérez-Ferriols,&nbsp;Sergio Santos-Alarcón,&nbsp;Antonio Sahuquillo-Torralba,&nbsp;Conrad Pujol-Marco,&nbsp;Raquel Rivera-Díaz,&nbsp;Isabel Belinchón-Romero,&nbsp;Diana Ruiz-Geneao,&nbsp;Alberto Romero-Maté,&nbsp;Ricardo Ruiz-Villaverde,&nbsp;Marta Ferrán-Farrés,&nbsp;Fernando Gallardo-Hernández,&nbsp;Manuel Almenara-Blasco,&nbsp;Jorge Alonso-Suárez,&nbsp;Álvaro González-Cantero,&nbsp;Elena Martínez-Lorenzo,&nbsp;José Manuel Fernández-Armenteros,&nbsp;Elena de Alcázar-Viladomiu,&nbsp;Javier García-Latasa,&nbsp;Vicenç Rocamora-Durant,&nbsp;Mariano Ara-Martín,&nbsp;Almudena Mateu-Puchades,&nbsp;Mar Llamas-Velasco,&nbsp;Eva Vilarrasa-Rull,&nbsp;Manel Velasco-Pastor,&nbsp;Pablo de la Cueva-Dobao,&nbsp;José Manuel Carrascosa-Carrillo,&nbsp;Antonio Martorell-Calatayud","doi":"10.1155/2024/5528484","DOIUrl":"https://doi.org/10.1155/2024/5528484","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Current psoriasis treatment goals emphasize achieving complete or near-complete skin clearance while preserving the quality of life, necessitating treatment modification for a suboptimal or inadequate response. Despite risankizumab’s demonstrated efficacy, evidence remains limited for patients switching from ustekinumab, particularly those with suboptimal or inadequate response. <i>Objective</i>. This study assesses risankizumab’s real-world effectiveness in patients with suboptimal response (PASI 2-3), inadequate response (PASI 3–5), or failure (PASI &gt;5) to ustekinumab, based on a multicenter retrospective cohort in Spain. <i>Method</i>. A multicenter retrospective study across 24 Spanish hospitals included 102 patients previously treated with ustekinumab and switched to risankizumab. <i>Results</i>. Out of 102 patients, 78 experienced ustekinumab treatment failure (PASI &gt;5), while 24 had an inadequate response (PASI 3–5), including 6 with a suboptimal response (PASI 2-3). Remarkably, after one year of treatment with risankizumab, all patients demonstrated improvement, achieving near-complete or complete skin clearance (PASI 0-1). <i>Conclusion</i>. Risankizumab displayed effectiveness in patients with suboptimal/inadequate response or treatment failure to ustekinumab, aligning with the current treatment goals of complete or near-complete skin clearance. These real-world results corroborate clinical trial data, emphasizing risankizumab’s potential as a powerful therapeutic alternative for this patient population. Further prospective studies are essential to validate these findings.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5528484","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141584096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis 杜匹单抗治疗中重度特应性皮炎的早期治疗反应和预测因素观察研究
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-07-10 DOI: 10.1155/2024/5782827
Sisi Deng, Huan Wang, Jiong Fu, Zhifang Zhai, Qiquan Chen, Zhiqiang Song

Background. Dupilumab has shown good effectiveness and safety in patients with moderate-to-severe atopic dermatitis. However, there is a lack of clinical data that focuses solely on the treatment response for the endpoint to observe the short-term goal (12 weeks) in the treatment-to-target (T2T) concept. Study on predictors of early treatment response is also limited. Objective. To evaluate the early effectiveness and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis and to identify possible predictors of response. Methods. Using a retrospective study method, patients with moderate-to-severe atopic dermatitis who received dupilumab for ≥12 weeks at the Southwest Hospital between September 2019 and April 2022 were included. Results. Totally 16.25% of patients achieved EASI75 after 4 weeks and 53.75% achieved EASI75 after 12 weeks. SCORAD, EASI, and NRS were 50.17 ± 17.35, 13.51 ± 12.33 and 7.10 ± 1.82 in turn at baseline, and decreased to 29.94 ± 15.01, 6.97 ± 7.92, 3.64 ± 1.39 and 14.96 ± 10.31, 3.05 ± 4.16, 2.19 ± 1.09 after 4 and 12 weeks, respectively, with statistically significant differences (p < 0.01). After 12 weeks, the changes in peripheral blood eosinophil count (decreased from (0.60 ± 0.43) ∗ 10^9/L to (0.30 ± 0.21) ∗ 10^9/L), total IgE level (decreased from 547.00 (179.00, 2167.50) IU/ml to 216.50 (106.00, 825.00) IU/ml), and LDH (decreased from (166.11 ± 171.59) IU/L to (67.54 ± 70.68) IU/L) from baseline were significant (p < 0.01). Elevated peripheral blood eosinophil counts might be associated with an inadequate response to dupilumab (SCORAD12w: p = 0.007; EASI12w: p = 0.003; NRS12w: p = 0.030). The most common adverse events were reactions at the injection site (6/80) and conjunctivitis (4/80). Conclusion. Dupilumab showed good early effectiveness and safety in real-world practice in Chinese patients with moderate-to-severe atopic dermatitis.

背景介绍杜比鲁单抗对中重度特应性皮炎患者具有良好的疗效和安全性。然而,在 "治疗到目标"(T2T)的概念中,缺乏仅以治疗反应为终点来观察短期目标(12 周)的临床数据。有关早期治疗反应预测因素的研究也很有限。研究目的评估杜比鲁单抗治疗中重度特应性皮炎的早期有效性和安全性,并确定可能的反应预测因素。方法:采用回顾性研究方法。采用回顾性研究方法,纳入2019年9月至2022年4月期间在西南医院接受杜度单抗治疗≥12周的中重度特应性皮炎患者。研究结果共有16.25%的患者在4周后达到EASI75,53.75%的患者在12周后达到EASI75。基线时SCORAD、EASI和NRS分别为(50.17±17.35)、(13.51±12.33)和(7.10±1.82),4周和12周后分别降至(29.94±15.01)、(6.97±7.92)、(3.64±1.39)和(14.96±10.31)、(3.05±4.16)、(2.19±1.09),差异有统计学意义(P <0.01)。12 周后,外周血嗜酸性粒细胞计数(从(0.60 ± 0.43)∗ 10^9/L 降至(0.30 ± 0.21)∗ 10^9/L)、总 IgE 水平(从 547.00(179.00,2167.50)IU/ml降至216.50(106.00,825.00)IU/ml),LDH(从(166.11 ± 171.59)IU/L降至(67.54 ± 70.68)IU/L)与基线相比均有显著性差异(p <0.01)。外周血嗜酸性粒细胞计数升高可能与对杜匹单抗的反应不充分有关(SCORAD12w:p = 0.007;EASI12w:p = 0.003;NRS12w:p = 0.030)。最常见的不良反应是注射部位反应(6/80)和结膜炎(4/80)。结论杜比鲁单抗在中国中重度特应性皮炎患者的实际治疗中显示出良好的早期有效性和安全性。
{"title":"An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis","authors":"Sisi Deng,&nbsp;Huan Wang,&nbsp;Jiong Fu,&nbsp;Zhifang Zhai,&nbsp;Qiquan Chen,&nbsp;Zhiqiang Song","doi":"10.1155/2024/5782827","DOIUrl":"https://doi.org/10.1155/2024/5782827","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Dupilumab has shown good effectiveness and safety in patients with moderate-to-severe atopic dermatitis. However, there is a lack of clinical data that focuses solely on the treatment response for the endpoint to observe the short-term goal (12 weeks) in the treatment-to-target (T2T) concept. Study on predictors of early treatment response is also limited. <i>Objective</i>. To evaluate the early effectiveness and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis and to identify possible predictors of response. <i>Methods</i>. Using a retrospective study method, patients with moderate-to-severe atopic dermatitis who received dupilumab for ≥12 weeks at the Southwest Hospital between September 2019 and April 2022 were included. <i>Results</i>. Totally 16.25% of patients achieved EASI75 after 4 weeks and 53.75% achieved EASI75 after 12 weeks. SCORAD, EASI, and NRS were 50.17 ± 17.35, 13.51 ± 12.33 and 7.10 ± 1.82 in turn at baseline, and decreased to 29.94 ± 15.01, 6.97 ± 7.92, 3.64 ± 1.39 and 14.96 ± 10.31, 3.05 ± 4.16, 2.19 ± 1.09 after 4 and 12 weeks, respectively, with statistically significant differences (<i>p</i> &lt; 0.01). After 12 weeks, the changes in peripheral blood eosinophil count (decreased from (0.60 ± 0.43) ∗ 10^9/L to (0.30 ± 0.21) ∗ 10^9/L), total IgE level (decreased from 547.00 (179.00, 2167.50) IU/ml to 216.50 (106.00, 825.00) IU/ml), and LDH (decreased from (166.11 ± 171.59) IU/L to (67.54 ± 70.68) IU/L) from baseline were significant (<i>p</i> &lt; 0.01). Elevated peripheral blood eosinophil counts might be associated with an inadequate response to dupilumab (SCORAD12w: <i>p</i> = 0.007; EASI12w: <i>p</i> = 0.003; NRS12w: <i>p</i> = 0.030). The most common adverse events were reactions at the injection site (6/80) and conjunctivitis (4/80). <i>Conclusion</i>. Dupilumab showed good early effectiveness and safety in real-world practice in Chinese patients with moderate-to-severe atopic dermatitis.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5782827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141584057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Lifestyle Affect Isotretinoin Tolerance in Patients with Acne? A Retrospective Cohort Study 生活方式会影响痤疮患者的异维A酸耐受性吗?一项回顾性队列研究
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-07-09 DOI: 10.1155/2024/4145694
Julia Lewandowska, Jan Kapała, Waldemar Placek, Agnieszka Owczarczyk-Saczonek

Isotretinoin (ISO) is a synthetic retinoid approved for the treatment of acne vulgaris. Despite satisfactory results, it is still controversial due to numerous adverse events (AE). However, there is a lack of literature examining the factors affecting the frequency and severity of these AEs. Lifestyle patterns may have an impact as they have the greatest impact on a person’s overall health. The aim of the research is to evaluate the impact of lifestyle patterns on the occurrence and severity of systemic ISO AEs in patients suffering from acne. A retrospective cohort study was conducted using a database of collected information about adults diagnosed with acne and treated with systemic ISO. Patients were divided into several groups according to their smoking status (nonsmokers, smokers), BMI (normal weight, overweight), physical activity (active, inactive), and compliance with the Mediterranean diet (adherent, not adherent). Considering all mentioned lifestyle factors, responders were categorized into healthy and unhealthy lifestyle groups. 124 adults with acne, undergoing systemic ISO therapy, made up the study group. There were generally no significant differences in patient characteristics across groups (P > 0.05). Almost all classes and subclasses of AEs showed no significant differences in groups (P > 0.05). ISO is still the most effective drug in the treatment of acne and despite the AEs, therapy should not be abandoned. Moreover, lifestyle factors such as physical activity, smoking, and eating habits do not affect the incidence and severity of AEs, which proves the safety of ISO regardless of unhealthy habits.

异维A酸(ISO)是一种合成维A酸,已被批准用于治疗寻常痤疮。尽管疗效令人满意,但由于其不良反应(AE)较多,因此仍备受争议。然而,目前还缺乏研究影响这些不良反应发生频率和严重程度的因素的文献。生活方式可能会产生影响,因为生活方式对人的整体健康影响最大。本研究旨在评估生活方式对痤疮患者全身 ISO AEs 发生率和严重程度的影响。研究人员利用收集到的有关确诊为痤疮并接受全身性 ISO 治疗的成年人的信息数据库,开展了一项回顾性队列研究。研究人员根据患者的吸烟状况(不吸烟、吸烟)、体重指数(正常体重、超重)、运动量(活跃、不活跃)和地中海饮食依从性(依从、不依从)将患者分为几组。考虑到所有上述生活方式因素,受试者被分为健康生活方式组和不健康生活方式组。研究小组由 124 名接受 ISO 系统治疗的成人痤疮患者组成。各组患者的特征一般无明显差异(P> 0.05)。几乎所有类别和亚类别的不良反应在各组间均无明显差异(P > 0.05)。ISO 仍是治疗痤疮最有效的药物,尽管存在不良反应,但不应放弃治疗。此外,体育锻炼、吸烟和饮食习惯等生活方式因素并不影响AEs的发生率和严重程度,这证明无论是否有不健康的生活习惯,ISO都是安全的。
{"title":"Does Lifestyle Affect Isotretinoin Tolerance in Patients with Acne? A Retrospective Cohort Study","authors":"Julia Lewandowska,&nbsp;Jan Kapała,&nbsp;Waldemar Placek,&nbsp;Agnieszka Owczarczyk-Saczonek","doi":"10.1155/2024/4145694","DOIUrl":"https://doi.org/10.1155/2024/4145694","url":null,"abstract":"<div>\u0000 <p>Isotretinoin (ISO) is a synthetic retinoid approved for the treatment of acne vulgaris. Despite satisfactory results, it is still controversial due to numerous adverse events (AE). However, there is a lack of literature examining the factors affecting the frequency and severity of these AEs. Lifestyle patterns may have an impact as they have the greatest impact on a person’s overall health. The aim of the research is to evaluate the impact of lifestyle patterns on the occurrence and severity of systemic ISO AEs in patients suffering from acne. A retrospective cohort study was conducted using a database of collected information about adults diagnosed with acne and treated with systemic ISO. Patients were divided into several groups according to their smoking status (nonsmokers, smokers), BMI (normal weight, overweight), physical activity (active, inactive), and compliance with the Mediterranean diet (adherent, not adherent). Considering all mentioned lifestyle factors, responders were categorized into healthy and unhealthy lifestyle groups. 124 adults with acne, undergoing systemic ISO therapy, made up the study group. There were generally no significant differences in patient characteristics across groups (<i>P</i> &gt; 0.05). Almost all classes and subclasses of AEs showed no significant differences in groups (<i>P</i> &gt; 0.05). ISO is still the most effective drug in the treatment of acne and despite the AEs, therapy should not be abandoned. Moreover, lifestyle factors such as physical activity, smoking, and eating habits do not affect the incidence and severity of AEs, which proves the safety of ISO regardless of unhealthy habits.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4145694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis 特应性皮炎控制工具在乌达替尼治疗特应性皮炎患者中的实用性
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-28 DOI: 10.1155/2024/4115539
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Background. Atopic dermatitis control tool (ADCT) is a patient-reported measure to assess disease control of atopic dermatitis (AD), consisting of the severity of symptoms, itch duration, bother, sleep, daily activities, and mood/emotions. Objectives. We evaluated the alterations of total and individual ADCT item scores during treatment with Janus kinase 1 inhibitor upadacitinib in AD patients. Methods. Forty-seven patients aged ≥12 years with moderate-to-severe AD were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. Total and individual ADCT item scores, eczema area, and severity index (EASI) and peak pruritus numerical rating scale (PP-NRS) were evaluated. Results. Before treatment, total ADCT correlated with EASI and PP-NRS. The median percent reduction at months 1, 3, and 6 of upadacitinib treatment was 80%, 76.2%, and 67.4% in total ADCT, 75.28%, 85.06%, and 81.73% in EASI, 66.67%, 75%, and 75% in PP-NRS, respectively, and percent reduction of total ADCT correlated with that of EASI and PP-NRS except for no correlations with that of EASI at month 1. The percent reduction of ADCT no.4 was the highest among the 6 items. Conclusions. These results suggest that changes in ADCT reflect the therapeutic effects of upadacitinib and that ADCT can be a treatment target for upadacitinib therapy. Upadacitinib might preferentially improve sleep disturbance.

背景:特应性皮炎控制工具(ADCT特应性皮炎控制工具(ADCT)是一种由患者报告的方法,用于评估特应性皮炎(AD)的疾病控制情况,包括症状严重程度、瘙痒持续时间、困扰、睡眠、日常活动和情绪/情感。研究目的我们评估了 AD 患者在接受 Janus 激酶 1 抑制剂 upadacitinib 治疗期间 ADCT 总分和单项评分的变化。方法47名年龄≥12岁的中重度AD患者接受了口服高达替尼15毫克/天加局部皮质类固醇治疗。评估了ADCT总分和单项得分、湿疹面积和严重程度指数(EASI)以及瘙痒峰值数字评分量表(PP-NRS)。结果显示治疗前,ADCT总分与EASI和PP-NRS相关。在达达替尼治疗的第1、3和6个月,总ADCT降低百分比的中位数分别为80%、76.2%和67.4%,EASI降低百分比的中位数分别为75.28%、85.06%和81.73%,PP-NRS降低百分比的中位数分别为66.67%、75%和75%,总ADCT降低百分比与EASI和PP-NRS相关,但在第1个月与EASI不相关。 在6个项目中,ADCT第4项的降低百分比最高。结论这些结果表明,ADCT的变化反映了达达替尼的治疗效果,ADCT可以作为达达替尼治疗的目标。奥达替尼可能会优先改善睡眠障碍。
{"title":"The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis","authors":"Teppei Hagino,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Naoko Kanda","doi":"10.1155/2024/4115539","DOIUrl":"https://doi.org/10.1155/2024/4115539","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Atopic dermatitis control tool (ADCT) is a patient-reported measure to assess disease control of atopic dermatitis (AD), consisting of the severity of symptoms, itch duration, bother, sleep, daily activities, and mood/emotions. <i>Objectives</i>. We evaluated the alterations of total and individual ADCT item scores during treatment with Janus kinase 1 inhibitor upadacitinib in AD patients. <i>Methods</i>. Forty-seven patients aged ≥12 years with moderate-to-severe AD were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. Total and individual ADCT item scores, eczema area, and severity index (EASI) and peak pruritus numerical rating scale (PP-NRS) were evaluated. <i>Results</i>. Before treatment, total ADCT correlated with EASI and PP-NRS. The median percent reduction at months 1, 3, and 6 of upadacitinib treatment was 80%, 76.2%, and 67.4% in total ADCT, 75.28%, 85.06%, and 81.73% in EASI, 66.67%, 75%, and 75% in PP-NRS, respectively, and percent reduction of total ADCT correlated with that of EASI and PP-NRS except for no correlations with that of EASI at month 1. The percent reduction of ADCT no.4 was the highest among the 6 items. <i>Conclusions</i>. These results suggest that changes in ADCT reflect the therapeutic effects of upadacitinib and that ADCT can be a treatment target for upadacitinib therapy. Upadacitinib might preferentially improve sleep disturbance.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4115539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Synergetic Roles of Stromal Vascular Fraction (SVF) and Extracellular Matrix (ECM) on Fat Graft Retention in Nude Mice 基质血管组分(SVF)和细胞外基质(ECM)对裸鼠脂肪移植固定的协同作用
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-25 DOI: 10.1155/2024/4200312
Lingling Sheng, Ziyou Yu, Yuan Fang, Danning Zheng, Weigang Cao

Background. Both stromal vascular fraction (SVF) and extracellular matrix (ECM) are of great concern to adipogenesis and angiogenesis. SVF and ECM are rich in adipose tissue and may provide structural and biochemical support and form a microenvironment for free granular fat. The present study was to investigate whether SVF-gel, a mixture of SVF and ECM harvested by mechanical emulsification, could improve the long-term volume retention of fat grafts. Methods. Human SVF-gel of different percentages was mixed with microfat. According to the percentages of SVF-gel into microfat, 4 groups were included in the study; they are the microfat group, 10% gel group, 30% gel group, and gel group. The fat grafts were transplanted in the subcutaneous layer on each flank in nude mice. The sample volume was measured to evaluate the fat retention rate 90 days post-transplantation. Tissue integrity, collagen content, numbers of viable adipocytes, and density of blood vessels were examined by further detection. Results. The retention volume rates in the 30% gel group and gel group were significantly higher than the microfat group and the 10% gel group (p < 0.05). Equivalent fat integrity was observed in the four groups. Higher collagen volume, enhanced mRNA expression of VEGF, TNF-α and adiponectin, more CD31-positive blood vessels, and more regenerative adipocytes were observed in the 30% gel group and the gel group. The fat tissue in the 30% gel group showed similar structures as the normal fat tissue, while almost of the tissue in the gel group exhibited as fibrous tissue. Conclusion. SVF-gel could improve fat graft retention while it came to a certain ratio into microfat via proangiogenic effect and fat regeneration which may be provided by SVF and ECM synergistically. SVF-gel-assisted fat grafting is a promising strategy to be used in clinical operations.

背景。基质血管成分(SVF)和细胞外基质(ECM)对脂肪生成和血管生成具有重要意义。脂肪组织中富含 SVF 和 ECM,可为游离颗粒脂肪提供结构和生化支持并形成微环境。本研究旨在探讨 SVF 凝胶(一种通过机械乳化获得的 SVF 和 ECM 混合物)能否改善脂肪移植的长期体积保持。研究方法将不同比例的人类 SVF 凝胶与微脂肪混合。根据 SVF 凝胶在微脂中所占比例的不同,研究分为四组,即微脂组、10% 凝胶组、30% 凝胶组和凝胶组。将脂肪移植到裸鼠两侧的皮下。测量样本体积以评估移植后 90 天的脂肪保留率。进一步检测组织的完整性、胶原蛋白含量、存活脂肪细胞数量和血管密度。结果显示30% 凝胶组和凝胶组的脂肪保留率明显高于微脂组和 10% 凝胶组(p < 0.05)。四组的脂肪完整性相当。30% 凝胶组和凝胶组的胶原体积更大,血管内皮生长因子、TNF-α 和脂肪连素的 mRNA 表达更强,CD31 阳性血管更多,再生脂肪细胞更多。30% 凝胶组的脂肪组织显示出与正常脂肪组织相似的结构,而凝胶组几乎所有组织都显示为纤维组织。结论SVF 凝胶可提高脂肪移植的保留率,同时通过 SVF 和 ECM 的协同作用,使其达到一定比例的微脂肪,促进血管生成和脂肪再生。SVF 凝胶辅助脂肪移植是一种很有前景的临床应用策略。
{"title":"The Synergetic Roles of Stromal Vascular Fraction (SVF) and Extracellular Matrix (ECM) on Fat Graft Retention in Nude Mice","authors":"Lingling Sheng,&nbsp;Ziyou Yu,&nbsp;Yuan Fang,&nbsp;Danning Zheng,&nbsp;Weigang Cao","doi":"10.1155/2024/4200312","DOIUrl":"https://doi.org/10.1155/2024/4200312","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Both stromal vascular fraction (SVF) and extracellular matrix (ECM) are of great concern to adipogenesis and angiogenesis. SVF and ECM are rich in adipose tissue and may provide structural and biochemical support and form a microenvironment for free granular fat. The present study was to investigate whether SVF-gel, a mixture of SVF and ECM harvested by mechanical emulsification, could improve the long-term volume retention of fat grafts. <i>Methods</i>. Human SVF-gel of different percentages was mixed with microfat. According to the percentages of SVF-gel into microfat, 4 groups were included in the study; they are the microfat group, 10% gel group, 30% gel group, and gel group. The fat grafts were transplanted in the subcutaneous layer on each flank in nude mice. The sample volume was measured to evaluate the fat retention rate 90 days post-transplantation. Tissue integrity, collagen content, numbers of viable adipocytes, and density of blood vessels were examined by further detection. <i>Results</i>. The retention volume rates in the 30% gel group and gel group were significantly higher than the microfat group and the 10% gel group (<i>p</i> &lt; 0.05). Equivalent fat integrity was observed in the four groups. Higher collagen volume, enhanced mRNA expression of VEGF, TNF-<i>α</i> and adiponectin, more CD31-positive blood vessels, and more regenerative adipocytes were observed in the 30% gel group and the gel group. The fat tissue in the 30% gel group showed similar structures as the normal fat tissue, while almost of the tissue in the gel group exhibited as fibrous tissue. <i>Conclusion</i>. SVF-gel could improve fat graft retention while it came to a certain ratio into microfat via proangiogenic effect and fat regeneration which may be provided by SVF and ECM synergistically. SVF-gel-assisted fat grafting is a promising strategy to be used in clinical operations.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4200312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Senile Gluteal Dermatosis: Update on Etiopathogenesis, Diagnostic Criteria, and Management 老年性臀部皮肤病:发病机制、诊断标准和管理的最新进展
IF 3.7 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-24 DOI: 10.1155/2024/5556190
Imran Majid, Dharmender Jairam, Kapil Baheti

Senile gluteal dermatosis (SGD) is an underdiagnosed skin condition that mostly affects the elderly. It appears as hyperkeratotic or lichenoid papules or plaques over the gluteal area, unilaterally or bilaterally. The etiopathogenesis of this condition is not yet known, but it is considered to be caused by prolonged mechanical stress on the affected area leading to neovascularization and epidermal hyperplasia. SGD poses unique problems in diagnosis and management due to its clinical characteristics and histological findings matching other common conditions. Due to its lesser-known status, it is frequently misdiagnosed as lichen simplex chronicus, inverse psoriasis, or cutaneous amyloidosis, which results in a variable response to treatment. Lifestyle modifications aiming at reducing pressure at the affected site remain the mainstay of treatment, but some reports have shown better results with topical or systemic retinoids. SGD is underreported in the scientific literature and is still not mentioned significantly in textbooks. This review attempts to give a thorough overview of SGD regarding its clinical presentation, etiology, pathogenesis, dermoscopy, diagnostic standards, differential diagnoses, and accessible treatments. Healthcare practitioners can enhance early recognition and provide the right care for afflicted people by raising knowledge and understanding of this disorder.

老年性臀部皮肤病(SGD)是一种诊断不足的皮肤病,主要影响老年人。它表现为单侧或双侧臀部角化过度或苔藓样丘疹或斑块。这种疾病的发病机理尚不清楚,但认为是由于患处长期受到机械压力导致血管新生和表皮增生所致。由于 SGD 的临床特征和组织学结果与其他常见疾病相似,因此给诊断和治疗带来了独特的问题。由于 SGD 鲜为人知,它经常被误诊为慢性单纯性苔藓、逆转性银屑病或皮肤淀粉样变性,导致对治疗的反应不一。旨在减轻患处压力的生活方式调整仍是治疗的主要方法,但一些报告显示,局部或全身使用维甲酸类药物的效果更好。科学文献中对 SGD 的报道较少,教科书中也很少提及。这篇综述试图对 SGD 的临床表现、病因、发病机制、皮肤镜检查、诊断标准、鉴别诊断和可采用的治疗方法进行全面概述。医护人员可以通过提高对该疾病的认识和理解,加强早期识别,并为患者提供正确的护理。
{"title":"Senile Gluteal Dermatosis: Update on Etiopathogenesis, Diagnostic Criteria, and Management","authors":"Imran Majid,&nbsp;Dharmender Jairam,&nbsp;Kapil Baheti","doi":"10.1155/2024/5556190","DOIUrl":"https://doi.org/10.1155/2024/5556190","url":null,"abstract":"<div>\u0000 <p>Senile gluteal dermatosis (SGD) is an underdiagnosed skin condition that mostly affects the elderly. It appears as hyperkeratotic or lichenoid papules or plaques over the gluteal area, unilaterally or bilaterally. The etiopathogenesis of this condition is not yet known, but it is considered to be caused by prolonged mechanical stress on the affected area leading to neovascularization and epidermal hyperplasia. SGD poses unique problems in diagnosis and management due to its clinical characteristics and histological findings matching other common conditions. Due to its lesser-known status, it is frequently misdiagnosed as lichen simplex chronicus, inverse psoriasis, or cutaneous amyloidosis, which results in a variable response to treatment. Lifestyle modifications aiming at reducing pressure at the affected site remain the mainstay of treatment, but some reports have shown better results with topical or systemic retinoids. SGD is underreported in the scientific literature and is still not mentioned significantly in textbooks. This review attempts to give a thorough overview of SGD regarding its clinical presentation, etiology, pathogenesis, dermoscopy, diagnostic standards, differential diagnoses, and accessible treatments. Healthcare practitioners can enhance early recognition and provide the right care for afflicted people by raising knowledge and understanding of this disorder.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5556190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Effectiveness of Two Old Immunosuppressant Drugs, Methotrexate and Azathioprine, in the Treatment of Lichen Planopilaris: A Randomized Clinical Trial 两种旧的免疫抑制剂甲氨蝶呤和硫唑嘌呤治疗扁平苔藓的临床疗效:随机临床试验
IF 3.6 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-19 DOI: 10.1155/2024/5556945
Mina Saber, Parisa Hajheidari, Farahnaz Fatemi Naeini, Fatemeh Mohaghegh

Background. Lichen planopilaris is the leading cause of cicatricial alopecia, and its management is challenging for dermatologists. It is a cell-mediated autoimmune disorder in which activated T-lymphocytes attack hair follicles. Aim. To compare the efficacy and safety of methotrexate versus azathioprine, two medications that affect lymphocyte function, in treating LPP. Methods. 32 LPP patients were randomly assigned to receive either 15 mg/week methotrexate or 2 mg/kg azathioprine for six months. Treatment efficacy was evaluated using the Lichen Planopilaris Activity Index (LPPAI), trichoscopy, and photography after 2, 4, and 6 months of treatment. Results. Both methotrexate and azathioprine groups showed significant improvements in LPPAI (P < 0.001) and perifollicular scaling on trichoscopy (P < 0.01). However, the two groups had no significant difference during the study. The azathioprine group significantly improved perifollicular erythema on trichoscopy (P = 0.002), but this was not significantly different from the methotrexate group (P = 0.69). Photographic assessment showed that more than 75% of patients in both groups improved without significant differences between the two groups. Conclusion. Methotrexate and azathioprine are two antilymphocyte medications which are both equally effective and well-tolerated for managing LPP. This trial is registered with IRCT20191006045005N2.

背景。扁平苔癣是卡他性脱发的主要病因,其治疗对皮肤科医生来说极具挑战性。这是一种细胞介导的自身免疫性疾病,活化的 T 淋巴细胞会攻击毛囊。研究目的比较甲氨蝶呤和硫唑嘌呤这两种影响淋巴细胞功能的药物在治疗白发性脱发症中的疗效和安全性。方法32 名 LPP 患者被随机分配接受每周 15 毫克的甲氨蝶呤或每公斤 2 毫克的硫唑嘌呤治疗,为期 6 个月。在治疗 2、4 和 6 个月后,使用扁平苔藓活动指数 (LPPAI)、毛囊镜检查和摄影来评估疗效。结果显示甲氨蝶呤组和硫唑嘌呤组的 LPPAI(P <0.001)和毛囊周围鳞屑(P <0.01)均有显著改善。不过,两组在研究期间没有明显差异。硫唑嘌呤组明显改善了毛囊周围红斑(P = 0.002),但与甲氨蝶呤组(P = 0.69)无明显差异。照片评估显示,两组中均有 75% 以上的患者病情有所改善,两组之间无明显差异。结论甲氨蝶呤和硫唑嘌呤这两种抗淋巴细胞药物对治疗 LPP 同样有效,且耐受性良好。本试验注册号为 IRCT20191006045005N2。
{"title":"Clinical Effectiveness of Two Old Immunosuppressant Drugs, Methotrexate and Azathioprine, in the Treatment of Lichen Planopilaris: A Randomized Clinical Trial","authors":"Mina Saber,&nbsp;Parisa Hajheidari,&nbsp;Farahnaz Fatemi Naeini,&nbsp;Fatemeh Mohaghegh","doi":"10.1155/2024/5556945","DOIUrl":"https://doi.org/10.1155/2024/5556945","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Lichen planopilaris is the leading cause of cicatricial alopecia, and its management is challenging for dermatologists. It is a cell-mediated autoimmune disorder in which activated T-lymphocytes attack hair follicles. <i>Aim</i>. To compare the efficacy and safety of methotrexate versus azathioprine, two medications that affect lymphocyte function, in treating LPP. <i>Methods</i>. 32 LPP patients were randomly assigned to receive either 15 mg/week methotrexate or 2 mg/kg azathioprine for six months. Treatment efficacy was evaluated using the Lichen Planopilaris Activity Index (LPPAI), trichoscopy, and photography after 2, 4, and 6 months of treatment. <i>Results</i>. Both methotrexate and azathioprine groups showed significant improvements in LPPAI (<i>P</i> &lt; 0.001) and perifollicular scaling on trichoscopy (<i>P</i> &lt; 0.01). However, the two groups had no significant difference during the study. The azathioprine group significantly improved perifollicular erythema on trichoscopy (<i>P</i> = 0.002), but this was not significantly different from the methotrexate group (<i>P</i> = 0.69). Photographic assessment showed that more than 75% of patients in both groups improved without significant differences between the two groups. <i>Conclusion</i>. Methotrexate and azathioprine are two antilymphocyte medications which are both equally effective and well-tolerated for managing LPP. This trial is registered with IRCT20191006045005N2.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5556945","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141430159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late-Onset Maculopapular Eruptions Associated with Elevated Varicella-Zoster Virus Complement-Fixing Antibody Titers following BNT162b2 mRNA COVID-19 Vaccination in Older Adult Japanese Patients: A Cross-Sectional Study 日本老年患者接种 BNT162b2 mRNA COVID-19 疫苗后,晚发性大疱性发作与水痘-带状疱疹病毒补体结合抗体滴度升高有关:一项横断面研究
IF 3.6 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-14 DOI: 10.1155/2024/2777924
Masahiro Oka, Yosuke Fujii, Sae Murakami

Diverse cutaneous adverse reactions associated with the messenger RNA-based BNT162b2 coronavirus disease 2019 (COVID-19) vaccine have been reported, usually developing within 3 weeks after the first vaccination. However, the long-term cutaneous effects of this vaccine remain poorly understood. We hypothesized that the BNT162b2 vaccine might trigger late-onset (>4 weeks after the first dose) maculopapular eruptions associated with elevated varicella-zoster virus (VZV) complement-fixing antibody (VZV-CF Ab) titers indicative of recent subclinical VZV reactivation. Therefore, we conducted a hospital-based cross-sectional study at the Dermatology Department of Kita-Harima Medical Center, Ono City, Japan, between July 1, 2021, and June 30, 2022, to investigate the correlations among the BNT162b2 vaccine, maculopapular eruptions, and VZV-CF Ab titers. Fifteen eligible patients (EPs) who experienced maculopapular eruptions on the trunk and extremities no earlier than 4 weeks after the first BNT162b2 vaccine dose and 12 control patients (CPs) were enrolled. The mean age of EPs and CPs was 73.7 and 77.6 years, respectively, and the median interval between the first BNT162b2 vaccination and onset of maculopapular eruptions was 90 days. The median VZV-CF Ab titer of EPs was significantly higher than that of CPs (×8 vs. ×4). Although people of all ages, except children aged ≤12 years, received BNT162b2 vaccinations, all EPs were aged ≥57 years. All EPs presented between July 2021 and March 2022. There were no EPs from April 2022 to December 2023. These results suggest that the BNT162b2 vaccine triggers elevated VZV-CF Ab titer-associated maculopapular eruptions as late-onset cutaneous adverse reactions in older adults. Furthermore, the observation that two EPs concurrently experienced delayed large local reactions, also known as COVID arm, along with maculopapular eruptions, supported our hypothesis. Our findings may improve the diagnosis of BNT162b2 vaccine-triggered elevated VZV-CF Ab titer-associated late-onset maculopapular eruptions and facilitate further investigation of diverse BNT162b2 vaccine-induced adverse events.

据报道,与基于信使核糖核酸的 BNT162b2 冠状病毒病 2019(COVID-19)疫苗相关的皮肤不良反应多种多样,通常在首次接种后 3 周内出现。然而,人们对这种疫苗的长期皮肤效应仍然知之甚少。我们假设,BNT162b2 疫苗可能会引发晚发(第一剂接种后 4 周)斑丘疹,与水痘-带状疱疹病毒(VZV)补体固定抗体(VZV-CF Ab)滴度升高有关,这表明近期亚临床 VZV 再激活。因此,我们于 2021 年 7 月 1 日至 2022 年 6 月 30 日在日本大野市北播磨医疗中心皮肤科进行了一项医院横断面研究,以探讨 BNT162b2 疫苗、斑丘疹和 VZV-CF Ab 滴度之间的相关性。15 名符合条件的患者(EPs)和 12 名对照组患者(CPs)在接种第一剂 BNT162b2 疫苗后 4 周内躯干和四肢出现斑丘疹。EPs 和 CPs 的平均年龄分别为 73.7 岁和 77.6 岁,首次接种 BNT162b2 疫苗与出现斑丘疹之间的中位间隔为 90 天。EPs的VZV-CF抗体滴度中位数明显高于CPs(×8对×4)。虽然除≤12岁的儿童外,所有年龄段的人都接种了BNT162b2疫苗,但所有EP的年龄都≥57岁。所有 EP 均在 2021 年 7 月至 2022 年 3 月期间发病。2022 年 4 月至 2023 年 12 月期间没有 EP。这些结果表明,BNT162b2 疫苗会引发与 VZV-CF Ab 滴度升高相关的斑丘疹,这是老年人晚发的皮肤不良反应。此外,观察到两名 EP 同时出现迟发性大面积局部反应(也称为 COVID arm)和斑丘疹,也支持了我们的假设。我们的研究结果可能会改善对 BNT162b2 疫苗引发的 VZV-CF Ab 滴度升高相关晚发性斑丘疹的诊断,并有助于进一步调查 BNT162b2 疫苗诱发的各种不良反应。
{"title":"Late-Onset Maculopapular Eruptions Associated with Elevated Varicella-Zoster Virus Complement-Fixing Antibody Titers following BNT162b2 mRNA COVID-19 Vaccination in Older Adult Japanese Patients: A Cross-Sectional Study","authors":"Masahiro Oka,&nbsp;Yosuke Fujii,&nbsp;Sae Murakami","doi":"10.1155/2024/2777924","DOIUrl":"https://doi.org/10.1155/2024/2777924","url":null,"abstract":"<div>\u0000 <p>Diverse cutaneous adverse reactions associated with the messenger RNA-based BNT162b2 coronavirus disease 2019 (COVID-19) vaccine have been reported, usually developing within 3 weeks after the first vaccination. However, the long-term cutaneous effects of this vaccine remain poorly understood. We hypothesized that the BNT162b2 vaccine might trigger late-onset (&gt;4 weeks after the first dose) maculopapular eruptions associated with elevated varicella-zoster virus (VZV) complement-fixing antibody (VZV-CF Ab) titers indicative of recent subclinical VZV reactivation. Therefore, we conducted a hospital-based cross-sectional study at the Dermatology Department of Kita-Harima Medical Center, Ono City, Japan, between July 1, 2021, and June 30, 2022, to investigate the correlations among the BNT162b2 vaccine, maculopapular eruptions, and VZV-CF Ab titers. Fifteen eligible patients (EPs) who experienced maculopapular eruptions on the trunk and extremities no earlier than 4 weeks after the first BNT162b2 vaccine dose and 12 control patients (CPs) were enrolled. The mean age of EPs and CPs was 73.7 and 77.6 years, respectively, and the median interval between the first BNT162b2 vaccination and onset of maculopapular eruptions was 90 days. The median VZV-CF Ab titer of EPs was significantly higher than that of CPs (×8 vs. ×4). Although people of all ages, except children aged ≤12 years, received BNT162b2 vaccinations, all EPs were aged ≥57 years. All EPs presented between July 2021 and March 2022. There were no EPs from April 2022 to December 2023. These results suggest that the BNT162b2 vaccine triggers elevated VZV-CF Ab titer-associated maculopapular eruptions as late-onset cutaneous adverse reactions in older adults. Furthermore, the observation that two EPs concurrently experienced delayed large local reactions, also known as COVID arm, along with maculopapular eruptions, supported our hypothesis. Our findings may improve the diagnosis of BNT162b2 vaccine-triggered elevated VZV-CF Ab titer-associated late-onset maculopapular eruptions and facilitate further investigation of diverse BNT162b2 vaccine-induced adverse events.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2777924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141326572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study 单剂量利桑珠单抗对银屑病的疗效:一项真实多中心研究
IF 3.6 4区 医学 Q1 DERMATOLOGY Pub Date : 2024-06-13 DOI: 10.1155/2024/4866592
Jorge Magdaleno-Tapial, José María Ortiz-Salvador, Sergio Santos-Alarcón, Isabel Belinchón-Romero, Antonio Sahuquillo-Torralba, Víctor González-Delgado, Javier Sabater-Abad, Miquel Armengot-Carbó, Juan Ignacio Marí-Ruíz, Almudena Mateu-Puchades, Javier Mataix-Díaz, Luca Schneller-Pavelescu, Rafael Carmena-Ramón, Antonio Martorell, José Luis Sánchez-Carazo

Background. Rapid efficacy is an important item to psoriasis patients. Risankizumab, a humanised immunoglobulin G1 monoclonal antibody that inhibits IL-23, has demonstrated early and sustained efficacy in patients with moderated-to-severe psoriasis. Effectiveness data in real world, particularly regarding short-term response, however, are scarce. Objective. To explore the short-term effectiveness of risankizumab in patients with moderate-severe psoriasis in normal clinical practice. Methods. This was an observational, retrospective, multicentre study carried out at thirteen hospitals in Valencia, Spain. It was conducted on a sample of adult outpatients over 18 years of age, diagnosed with moderate-to-severe psoriasis who received at least one subcutaneous injection of 150 mg of risankizumab. Psoriasis Area and Severity Index (PASI) was used to assess the short-term (4 weeks) effectiveness of risankizumab. Results. One hundred and sixteen patients (63.8% men) with a mean age (standard deviation (SD)) of 50 (16) years were included in the study. 90.6% were overweight or obese, and 22.7% were biologic-naïve. The mean (SD) PASI score decreased from 11.9 (7.2) at the baseline to 3.3 (2.7) at week 4, with a median (SD) PASI score reduction of 8.6 (2.3) (p < 0.05). The absolute PASI score of <2 was reached by 52.6% of patients. Overall, PASI scores of 75, 90, and 100 were achieved in 56%, 37.1%, and 25.9% of patients, respectively, at week 4. PASI 90 was achieved by a significantly higher proportion of naïve patients than biologic-experience failure patients (59.3% vs. 30.3%; p = 0.01). Conclusion. This study, which reflects our initial risankizumab experience in a real-life setting, seems to show quick effectiveness in psoriasis treatment after one single dose. This trial is registered with NCT04862286.

背景。对银屑病患者来说,快速疗效是一个重要的项目。利桑珠单抗是一种抑制 IL-23 的人源化免疫球蛋白 G1 单克隆抗体,对中度至重度银屑病患者具有早期和持续的疗效。然而,现实世界中的疗效数据,尤其是有关短期反应的数据却很少。研究目的探讨利桑珠单抗在正常临床实践中对中度至重度银屑病患者的短期疗效。方法。这是一项观察性、回顾性、多中心研究,在西班牙巴伦西亚的 13 家医院进行。研究对象为 18 岁以上、被诊断为中度至重度银屑病、至少接受过一次 150 毫克利桑珠单抗皮下注射的成年门诊患者。银屑病面积和严重程度指数(PASI)用于评估利坦珠单抗的短期(4 周)疗效。研究结果116名患者(63.8%为男性)参加了研究,平均年龄(标准差(SD))为50(16)岁。90.6%的患者超重或肥胖,22.7%的患者对生物制剂一无所知。平均(标清)PASI评分从基线时的11.9(7.2)分降至第4周时的3.3(2.7)分,中位(标清)PASI评分降低了8.6(2.3)分(p < 0.05)。52.6%的患者 PASI 绝对值达到 2 分。总体而言,第 4 周时分别有 56%、37.1% 和 25.9% 的患者 PASI 达到 75、90 和 100 分。达到 PASI 90 分的新患者比例明显高于有生物制剂治疗经验的失败患者(59.3% 对 30.3%;P = 0.01)。结论这项研究反映了我们在现实生活中使用利桑珠单抗的初步经验,似乎显示出单次用药后对银屑病治疗的快速疗效。该试验已在 NCT04862286 上注册。
{"title":"One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study","authors":"Jorge Magdaleno-Tapial,&nbsp;José María Ortiz-Salvador,&nbsp;Sergio Santos-Alarcón,&nbsp;Isabel Belinchón-Romero,&nbsp;Antonio Sahuquillo-Torralba,&nbsp;Víctor González-Delgado,&nbsp;Javier Sabater-Abad,&nbsp;Miquel Armengot-Carbó,&nbsp;Juan Ignacio Marí-Ruíz,&nbsp;Almudena Mateu-Puchades,&nbsp;Javier Mataix-Díaz,&nbsp;Luca Schneller-Pavelescu,&nbsp;Rafael Carmena-Ramón,&nbsp;Antonio Martorell,&nbsp;José Luis Sánchez-Carazo","doi":"10.1155/2024/4866592","DOIUrl":"https://doi.org/10.1155/2024/4866592","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Rapid efficacy is an important item to psoriasis patients. Risankizumab, a humanised immunoglobulin G1 monoclonal antibody that inhibits IL-23, has demonstrated early and sustained efficacy in patients with moderated-to-severe psoriasis. Effectiveness data in real world, particularly regarding short-term response, however, are scarce. <i>Objective</i>. To explore the short-term effectiveness of risankizumab in patients with moderate-severe psoriasis in normal clinical practice. <i>Methods</i>. This was an observational, retrospective, multicentre study carried out at thirteen hospitals in Valencia, Spain. It was conducted on a sample of adult outpatients over 18 years of age, diagnosed with moderate-to-severe psoriasis who received at least one subcutaneous injection of 150 mg of risankizumab. Psoriasis Area and Severity Index (PASI) was used to assess the short-term (4 weeks) effectiveness of risankizumab. <i>Results</i>. One hundred and sixteen patients (63.8% men) with a mean age (standard deviation (SD)) of 50 (16) years were included in the study. 90.6% were overweight or obese, and 22.7% were biologic-naïve. The mean (SD) PASI score decreased from 11.9 (7.2) at the baseline to 3.3 (2.7) at week 4, with a median (SD) PASI score reduction of 8.6 (2.3) (<i>p</i> &lt; 0.05). The absolute PASI score of &lt;2 was reached by 52.6% of patients. Overall, PASI scores of 75, 90, and 100 were achieved in 56%, 37.1%, and 25.9% of patients, respectively, at week 4. PASI 90 was achieved by a significantly higher proportion of naïve patients than biologic-experience failure patients (59.3% vs. 30.3%; <i>p</i> = 0.01). <i>Conclusion</i>. This study, which reflects our initial risankizumab experience in a real-life setting, seems to show quick effectiveness in psoriasis treatment after one single dose. This trial is registered with NCT04862286.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4866592","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141315502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatologic Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1